Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Appl Thromb Hemost. 2013 Jun;19(3):282-8. doi: 10.1177/1076029612461067. Epub 2012 Oct 11.

Benefits and risks of preventing thromboembolism with enoxaparin in patients with general surgery in real world--the CLEVER study.

Author information

  • 1Klinikum Friedrichstadt, Dresden, Germany. schellong-se@khdf.de

Abstract

BACKGROUND:

We aimed to document enoxaparin use in real world and identify the risk factors for bleeding complications.

METHODS:

Postauthorization study in 448 surgical patients receiving enoxaparin prophylaxis. Complete compression ultrasound (CCUS) was performed at day 10 ± 3.

RESULTS:

During treatment, 11 of 448 patients had suspected deep venous thrombosis (DVT) but none confirmed. One patient had symptoms of pulmonary embolism ([PE] 0.22%; 95% confidence interval [CI] -0.21-0.66). There were no asymptomatic cases detected upon CCUS. At the 90-day follow-up, 4 (0.9%) of the 440 patients had DVT symptoms (95% CI 0.02-1.80) and none had PE; 5.4% had major and 11.6% any type of bleeding complications. Major bleeding was more frequent in those with kidney disease (odds ratio [OR] 5.53), those who are bedridden (OR 5.49), those with peridural indwelling catheters (OR 4.01), and those on nonsteroidal anti-inflammatory drugs (OR 3.33).

CONCLUSIONS:

Enoxaparin is effective and safe in surgical patients to prevent venous thromboembolism.

KEYWORDS:

complete compression ultrasound; enoxaparin; major bleeding; predictors; surgery; venous thromboembolism

PMID:
23064219
DOI:
10.1177/1076029612461067
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center